A Phase 1 interventional study of Evacetrapib and Simvastatin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-10.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to investigate how the body responds to evacetrapib and to evaluate the safety and the effect of evacetrapib, alone and in combination with selected statins, in healthy Chinese participants. The study has 2 parts. Part one will last up to 4 weeks and part two will last up to 5 weeks, not including screening. Participants may only enroll in one part.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants:
Exclusion Criteria:
Have used or intend to use over-the-counter or prescription medications (including vitamins/mineral supplements) or TCM 14 days prior to the first dose and during the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
Drug: Evacetrapib
Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
Drug: Evacetrapib
Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
Drug: Simvastatin
Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
Drug: Evacetrapib · Drug: Simvastatin
Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
Drug: Atorvastatin
Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
Drug: Evacetrapib · Drug: Atorvastatin
Administered orally.
Also known as: LY2484595
Administered orally.
Administered orally.
Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib
Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.
Time frame: Part 1: Day 1 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours Postdose
PK: Maximum Concentration (Cmax) of Evacetrapib
Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.
Time frame: Part 1: Day 1 and Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours Postdose
PK: Time to Maximum Concentration (Tmax) of Evacetrapib
Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.
Time frame: Part 1: Day 1 Predose on Day 1 or Day 14 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours postdose. Part 2: Predose on Day 14 at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose.
PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin
Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).
Time frame: Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose
PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin
Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.
Time frame: Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose.
PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin
Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.
Time frame: Part 2: Predose on Day 14 and 22 and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose.
Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)
Time frame: Single Dose Day 2 and Multiple Dose Day 22
| Milestone | Cohort A: Evacetrapib Single and Multiple Dose | Cohort B: Evacetrapib and Simvastatin | Cohort C: Evacetrapib and Atorvastatin |
|---|---|---|---|
| Started | 16 | 24 | 22 |
| Received at least one dose of study drug | 16 | 24 | 22 |
| Completed | 16 | 23 | 22 |
| Not completed | 0 | 1 | 0 |
| Withdrew: No reason given | 0 | 1 | 0 |
| Milestone | Cohort A: Evacetrapib Single and Multiple Dose | Cohort B: Evacetrapib and Simvastatin | Cohort C: Evacetrapib and Atorvastatin |
|---|---|---|---|
| Started | 16 | 23 | 22 |
| Completed | 16 | 23 | 22 |
| Not completed | 0 | 0 | 0 |
| Milestone | Cohort A: Evacetrapib Single and Multiple Dose | Cohort B: Evacetrapib and Simvastatin | Cohort C: Evacetrapib and Atorvastatin |
|---|---|---|---|
| Started | 0 | 23 | 22 |
| Completed | 0 | 22 | 22 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.
| nanogram * hour per milliliter (ng*h/mL) | Evacetrapib Single and Multiple Dose |
|---|---|
| Day 1 | 7700 ± 74 |
| Day 14 | 23600 ± 33 |
Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.
| ng/mL | Evacetrapib Single and Multiple Dose |
|---|---|
| Single Dose Day 1 | 418 ± 118 |
| Multiple Dose Day 14 | 954 ± 52 |
Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.
| hours (h) | Evacetrapib Single and Multiple Dose |
|---|---|
| Single Dose Day 1 | 3.00 (2.00 to 6.00) |
| Daily Dose Day 14 | 3.00 (2.00 to 4.00) |
Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).
| ng*h/mL | Evacetrapib Daily and Simvastatin | Evacetrapib Daily and Atorvastatin |
|---|---|---|
| Days 5-14 | 10700 ± 36 | 10600 ± 30 |
| Days 15-22 | 9640 ± 48 | 9480 ± 53 |
Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.
| ng/mL | Evacetrapib Daily and Simvastatin | Evactrapib Daily and Atorvastatin |
|---|---|---|
| Days 5-14 | 1180 ± 52 | 1120 ± 36 |
| Days 15- 22 | 1020 ± 68 | 1000 ± 73 |
Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.
| h | Evacetrapib Daily and Simvastatin | Evacetrapib Daily and Atrovastatin |
|---|---|---|
| Days 5-14 | 3.00 (2.00 to 4.00) | 3.00 (2.00 to 6.00) |
| Days 15- 22 | 3.00 (2.00 to 4.00) | 3.00 (2.00 to 4.00) |
| millimoles per liter (mmol/L) | Evacetrapib Single Dose Day 2 | Evacetrapib Multiple Dose Day 22 |
|---|---|---|
| HDL-C | 1.641 ± 0.211 | 2.676 ± 0.373 |
| LDL-C | 2.289 ± 0.483 | 1.241 ± 0.574 |
| TG | 0.984 ± 0.312 | 1.221 ± 0.356 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Evacetrapib Single Cohort A | — | 0/16 (0%) | 0/16 (0%) |
| Evacetrapib Multiple | — | 0/16 (0%) | 0/16 (0%) |
| Simvastatin | — | 0/24 (0%) | 0/24 (0%) |
| Evacetrapib Single Cohort B | — | 0/23 (0%) | 0/23 (0%) |
| Evacetrapib and Simvastatin | — | 0/23 (0%) | 0/23 (0%) |
| Atorvastatin | — | 0/22 (0%) | 0/22 (0%) |
| Evacetrapib Single Cohort C | — | 0/22 (0%) | 0/22 (0%) |
| Evacetrapib and Atorvastatin | — | 0/22 (0%) | 0/22 (0%) |
Participants who received at least one dose of study drug.
| Age, Continuous(years) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Mean | 29.1 ± 8.0 | 27.5 ± 2.9 | 27.9 ± 4.9 | 28.02 ± 5.25 |
| Sex: Female, Male(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Female | 3 | 0 | 2 | 5 |
| Male | 13 | 24 | 20 | 57 |
| Race (NIH/OMB)(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 16 | 24 | 22 | 62 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| China | 16 | 24 | 22 | 62 |
The record gives a start of Jun 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Evacetrapib · Simvastatin · Atorvastatin